Latest News

Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

April 16th 2024

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer
Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024

Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC
Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC

April 8th 2024

Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC

April 7th 2024